Effect of SARSCoV2 (COVID-19) Vaccination in Type 1 Diabetes (CoVaxT1D)

Type 1 Diabetes Clinical Trial

— CoVaxT1D  

Official title:

Effect of SARSCoV2 Vaccination in Type 1 Diabetes (CoVaxT1D)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04905823
• Other study ID #: CoVaxT1D
• Status: Completed
• Start date: March 31, 2021
• Est. completion date: June 30, 2022

Study information

• Verified date: May 2023
• Source: University of Milan
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Given the high risk of severe SARS-CoV-2 infection, patients with T1D and T2D should represent a priority group to receive the SARS-CoV-2 vaccine. There are currently no studies on diabetic population response to mRNA COVID-19 vaccines. Therefore, in this observational cohort study, investigators will retrospectively analyze the safety and immunogenicity of the mRNA vaccines in eliciting both the humoral and cellular immune response in a subset of patients with T1D who already underwent blood sampling for measuring humoral response against SARSCoV2 for healthcare purposes and based on the clinical practice guidelines. Results will be compared with those obtained in non-diabetic individuals or in patients with non-autoimmune diabetes (T2D).

Description:

Since the beginning of the COVID-19 pandemic in March 2020, more than 160 million people have suffered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and more than 3 million deaths occurred. Currently, two vaccines using messenger RNA (mRNA) technology and lipid nanoparticle (LNP) delivery systems have been approved for emergency use by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA): mRNA-1273, Moderna, and BNT162b2, Pfizer. In phase-3 clinical trials, two injections of these vaccines, spaced 21 and 28 days apart, showed efficacy higher than 90% in preventing symptomatic infections. The reported humoral immunity response with the mRNA vaccines was similar to that elicited by convalescent serum obtained from patients who recovered from Covid-19 infection. However, the T-cell mediated reaction to these vaccines remains to be fully elucidated. Diabetic patients are at higher risk of developing severe SARS-CoV-2 infection. In a large observational cohort study, the overall risks of fatal or critical care unit-treated COVID-19 were significantly elevated for patients with diabetes compared with the general population. While patients with Type 2 diabetes (T2D) are usually older and with a higher comorbidity index, the altered immune functions seem to play a major role in patients with Type 1 Diabetes (T1D). Altough an impaired immune response to vaccination was hypothesized in diabetic patients, no evidence has been provided. Given the high risk of severe SARS-CoV-2 infection, patients with T1D and T2D should represent a priority group to receive the COVID-19 vaccine. There are currently no studies on diabetic population response to mRNA COVID-19 vaccines. Therefore, in this observational cohort study, investigators will retrospectively analyze the safety and immunogenicity of the mRNA vaccines in eliciting both the humoral and cellular immune response in a subset of patients with T1D, T2D and in non-diabetic individuals who already underwent blood sampling for measuring humoral response against SARSCoV2 for healthcare purposes and based on the clinical practice guidelines.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 600
• Est. completion date: June 30, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria for patients with type 1 diabetes:

• age >16

• History of type 1 diabetes

• previous blood test in search for SARSCoV2 antibodies

• willingness to provide informed consent

Exclusion Criteria for patients with type 1 diabetes:

• age <16 years

• Systemic infections

• Diabetic ketoacidosis in the past 6 weeks

• COVID-19 diagnosis in the previous 6 months

Inclusion Criteria for non-diabetic subjects:

• age >16

• No previous history of diabetes

• previous blood test in search for SARSCoV2 antibodies

• willingness to provide informed consent

Exclusion Criteria for non-diabetic subjects:

• age <16 years

• Systemic infections

• COVID-19 diagnosis in the previous 6 months

Inclusion Criteria for patients with type 2 diabetes:

• age >16

• History of type 2 diabetes but no evidence of autoantibodies

• previous blood test in search for SARSCoV2 antibodies

• willingness to provide informed consent

Exclusion Criteria for patients with type 2 diabetes:

• age <16 years

• Systemic infections

• COVID-19 diagnosis in the previous 6 months

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Diagnostic Test:
• blood test
assessment of humoral, immune cell response and glycemia

Locations

Country	Name	City	State
Italy	ASST FBF-Sacco P.O. Sacco	Milan	MI

Sponsors (2)

Lead Sponsor	Collaborator
Paolo Fiorina, MD	ASST Fatebenefratelli Sacco

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events	number of adverse events after SARSCov2 vaccination	change from baseline number at 2 months
Secondary	Humoral response	Levels of antibodies detected against SARSCoV2	change from baseline levels at 2 months
Secondary	Immune cell response	T cell response quantification	change from baseline levels at 2 months
Secondary	Values of continuous glucose monitoring	analysis of glycemic profile measured with continuous glucose monitoring	change from baseline values at 2 months